Deals In Depth: August 2019
Celgene was involved in the two largest alliances of August: one to divest a product to satisfy regulatory conditions of its acquisition by Bristol-Myers Squibb and the other to develop adoptive cell therapies. There was continued acquisition activity in the CDMO market as Cambrex was bought out by investment firm Permira. Biopharma and device funding were both down.
You may also be interested in...
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.